Cargando…

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvarado-Miranda, Alberto, Lara-Medina, Fernando Ulises, Muñoz-Montaño, Wendy R., Zinser-Sierra, Juan W., Galeana, Paula Anel Cabrera, Garza, Cynthia Villarreal, Sanchez Benitez, Daniel, Limón Rodríguez, Jesús Alberto, Arce Salinas, Claudia Haydee, Guijosa, Alberto, Arrieta, Oscar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377785/ https://www.ncbi.nlm.nih.gov/pubmed/37504314 http://dx.doi.org/10.3390/curroncol30070454

Ejemplares similares

Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular
por: Reynoso-Noverón, Nancy, et al.
Publicado: (2017)

Characterization of triple negative breast cancer gene expression profiles in Mexican patients
por: Ortiz Valdez, Eric, et al.
Publicado: (2022)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2009)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Sex-specific regulation of inhibition and network activity by local aromatase in the mouse hippocampus
por: Hernández-Vivanco, Alicia, et al.
Publicado: (2022)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
por: GHIMENTI, CHIARA, et al.
Publicado: (2013)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
por: Catalán, Rodrigo, et al.
Publicado: (2020)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients
por: Yuan, Yuan, et al.
Publicado: (2021)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
por: Bao, Yuwen, et al.
Publicado: (2022)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
por: Gori, Stefania, et al.
Publicado: (2016)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature
por: Bongiovanni, Alberto, et al.
Publicado: (2014)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Modulation of Aromatase by Phytoestrogens
por: Lephart, Edwin D.
Publicado: (2015)

Aromatase in the Human Brain
por: Azcoitia, Iñigo, et al.
Publicado: (2021)

Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
por: Guijosa, Alberto, et al.
Publicado: (2022)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Epitope Characterization of an Aromatase Monoclonal Antibody Suitable for the Assessment of Intratumoral Aromatase Activity
por: Hong, Yanyan, et al.
Publicado: (2009)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Expression and clinical significance of HER2/neu, aromatase P450 and adhesion molecule CD24 in endometrial cancer
por: Guan, Liyun, et al.
Publicado: (2023)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months’ Remission with Lapatinib plus Capecitabine
por: Mailliez, Audrey, et al.
Publicado: (2014)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
por: Lee, Jieun, et al.
Publicado: (2017)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
por: Hu, Yiyi, et al.
Publicado: (2023)

Capecitabine-induced Leukoencephalopathy
por: Yoshimura, Kenji, et al.
Publicado: (2018)

Capecitabine-Induced Enterocolitis
por: Khan, Muzammil, et al.
Publicado: (2022)

Implementation of Wavelet-Transform-Based Algorithms in an FPGA for Heart Rate and RT Interval Automatic Measurements in Real Time: Application in a Long-Term Ambulatory Electrocardiogram Monitor
por: García Limón, José Alberto, et al.
Publicado: (2023)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

SUSY Meets Her Twin
por: Katz, Andrey, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6kguqa16j70r25mqh1fp8eshvr